Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

TRANSHESC

Financiado

Cerrado

Generation of stable transgenic embryonic stem cell lines

Human embryonic stem cells (hESC) are pluripotent cells derived from blastocyst stage early embryos. Since the original publication a vast number of studies have described the differentiation of hESC and their potential in regener... ver más

31/08/2010

USFD

243K€

Presupuesto del proyecto: 243K€

Líder del proyecto

THE UNIVERSITY OF SHEFFIELD No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2010-08-31 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

USFD

0.00€ | Lider

Proyectos interesantes

EU-hPSCreg

Medical Technol...

Data Science

549K€ Cerrado

REPROWORM

Medical Technol...

Biotechnology

1M€ Cerrado

PLURIMES

Medical Technol...

Biotechnology

8M€ Cerrado

FORMAT

Medical Technol...

Biotechnology

150K€ Cerrado

CELLNAIVETY

Medical Technol...

Biotechnology

2M€ Cerrado

SAF2015-66105-R

Medical Technol...

Biotechnology

Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

THE UNIVERSITY OF SHEFFIELD No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 243K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Human embryonic stem cells (hESC) are pluripotent cells derived from blastocyst stage early embryos. Since the original publication a vast number of studies have described the differentiation of hESC and their potential in regenerative medicine. It is now well known that hESC might be used in cell replacement therapies in a number of severe degenrative diseases like Type I diabetes or Parkinson’s disease. In addition, hESCs and their derivatives could be used as tools in discovering new drugs and in understanding mechanisms of genetic diseases. HESC applications could also be used in toxicological studies reducing the need of animal experiments. Genetic manipulation of hESC will be a crucial issue in a variety of future studies. To elucidate the role of any given gene for example in directed differentiation or pathogenesis the loss- and gain-of gene function approaches are of major importance. Also, considering the potential therapeutic applications of the hESC their genetic modifications may be necessary. The first part of this proposal is designed to improve and test novel efficient and safe transposon-based gene transfer method in generating conditional transgenic hESC lines. Of special interest is the use of insulator elements around transgene to assure nonbiased expression of the integrated sequences. Several reports have indicated that in long term hESC cultures the cells aquire chromosomal aberrations. The observed karyotypic changes probably reflect the progressive adaptation of self-renewing cells to their culture conditions. This process has parallels with malignant transformation. Changes observed in hESC in culture reflect tumorigenic events that occur in vivo, particularly in testicular germ cell tumors (TGCT). A recent report indicated the formation of a chromosomal homogeneous staining region (HSR) in some hESC lines, a feature almost a hallmark of cancer cells. The HSR represents an amplified small chromosomal region most likely containing gene

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores